CN104688758A - Medicine composition of compound saikosaponin D and application of medicine composition - Google Patents
Medicine composition of compound saikosaponin D and application of medicine composition Download PDFInfo
- Publication number
- CN104688758A CN104688758A CN201510052476.4A CN201510052476A CN104688758A CN 104688758 A CN104688758 A CN 104688758A CN 201510052476 A CN201510052476 A CN 201510052476A CN 104688758 A CN104688758 A CN 104688758A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- saikosaponin
- taurine
- medicine
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a medicine composition for preventing and treating hepatic fibrosis, tumors and especially liver cancer. The medicine composition comprises saikosaponin D and taurine, and is prepared by supplementing conventional medicinal auxiliary materials by virtue of a conventional process. According to the medicine composition disclosed by the invention, taurine has synergistic action on the anti-hepatic-fibrosis performance of saikosaponin D, and can also be used for improving the anti-tumor especially anti-liver-cancer effects of saikosaponin D.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition be made up of by a certain percentage saikosaponin D and taurine and preparation method thereof; and pharmaceutical composition treats and/or prevents the application in the medicine of hepatic fibrosis, tumor especially liver cancer diseases in preparation, belongs to medical art.
Background technology
Radix Bupleuri nature and flavor are bitter, cool, enter liver and gall warp, reconciling superficies and interior, soothing the liver, yang invigorating.Control alternate attack of chill and fever, fullness in the chest and hypochondriac pain, bitter taste is deaf, headache and dizziness, malaria, lower sharp proctoptosis, menoxenia, uterine prolapse.Modern pharmacological research shows that Radix Bupleuri has antiinflammatory, immunomodulating, anti-hepatic fibrosis and the multiple pharmacologically active such as to protect the liver.Saikosaponin D be separated from Chinese medicine Radix Bupleuri, one of composition that the pharmacologically active that extracts is the strongest, there is the pharmacological actions such as antipyretic, analgesia and antiinflammatory.
Research in recent years shows, saikosaponin D (SSd) is the pentacyclic triterpene neat fruit alkane type derivant separated from Radix Bupleuri root, there is multiple pharmacological activity, as antiinflammatory, antitumor, anti-kidney hepatic fibrosis etc., saikosaponin D is by direct cytotoxicity or affect tumor cell adhesion and cell death inducing etc., suppress or kill people's pulmonary carcinoma, gastric cancer, hepatocarcinoma, the tumor cells such as leukaemia and mice transplantability S-180 solid tumor, its antineoplastic action cause scholar show great attention to (Liu Zhenguo etc. the preventive effect that saikosaponin D is formed experimental hepatocellular carcinoma in rats. XI AN JIAOTONG UNIVERSITY Subject Index, 2007, 28 (6): 645).In clinical practice and modern study process, find that saikoside has hepatotoxicity gradually, its hepatic injury mechanism and approach main with multipath oxidativestress damage about (Sun Rong etc. saikoside is to the Pharmacology progress of liver, Chinese experimental pharmacology of Chinese medical formulae magazine, 2011,17 (17): 298).
Taurine has another name called 2-aminoethyl sulfonic acid, is a kind of beta-amino acids be transformed by sulfur-containing amino acid, and dissociating and be present in various tissue in human body, is the free amino acid that animal body intensive amount enriches the most.Taurine is as the effective ingredient of rare Chinese medicine " Calculus Bovis ", and it has heat clearing away, analgesia, blood pressure lowering, blood sugar lowering, increase immunity, mends gallbladder, protecting liver and detoxication, adjustment antiotasis and correct the multiple pharmacological effect such as vivo acid is unbalance.Research finds, taurine can alleviate the hepar damnification caused by Acute cadmium toxication, alleviates cadmium and resists oxidasic suppression, avoid GSH irritability to raise, remove the suppression to GSH-Px activity, to the protective effect of hepatic lipid peroxidation damage; Taurine has the effect of anti-hepatic fibrosis, rat blood serum ALT, hyaluronic acid (HA) and III procollagen type (PC III) level can be reduced, the expression of obvious reduction TGF-β 1, improve liver cell pigment P450 and cytochrome b5 content simultaneously, and impel the apoptosis on hepatic stellate cells be activated, obviously alleviate fibrosis; Taurine can suppress hepatocellular apoptosis and the protective effect to Ischemia-reperfusion Injury in Rat, and the ischemia of liver and ischemical reperfusion injury can not only cause hepatic necrosis, also can cause hepatocellular apoptosis, and taurine significantly can suppress CCl
4the hepatocellular apoptosis of induction, the mechanism of inhibited apoptosis is then expressed with enhancing Bc1-2 and suppresses the expression of Bax and TGF-β relevant.
The hepatic fibrosis be in progress for the anti-hepatitis caused by virus, antibacterial, invasive organism, drug induced injury, immune mediating damage that improves medicine and specificity and nonspecific lipid liver institute about the compositions of saikosaponin D and taurine, antitumor especially hepatocarcinoma have no and to report and patent discloses.
Summary of the invention
The invention provides one and there is anti-hepatic fibrosis, antitumor action, especially pharmaceutical composition, the preparation method and its usage of prevention and therapy hepatocarcinoma.
Pharmaceutical composition of the present invention is made up of saikosaponin D and taurine, and the acceptable adjuvant of medicine.The compound medicine of saikosaponin D and taurine composition; the hepatitis of antagonism caused by virus, antibacterial, invasive organism, drug induced injury, immune mediating damage and specificity and nonspecific lipid liver the hepatic fibrosis that is in progress there is potentiation, also can improve the antitumor especially hepatocarcinoma effect of saikosaponin D.
Pharmaceutical composition of the present invention is made up of saikosaponin D and taurine, can add the inosine, coenzyme A, the one in Glucuronic acid lactone or or several that have and improve liver metabolism if desired.
Compound medicinal formulation of the present invention, every 1000 dosage units, containing saikosaponin D 0.1 ~ 100 part, containing taurine 0.1 ~ 800 part.Preferred containing saikosaponin D 0.1 ~ 50 part, containing taurine 0.1 ~ 300 part.Preferred containing saikosaponin D 0.1 ~ 20 part further, containing taurine 0.5 ~ 50 part.
Prevention and therapy tumor is being prepared in pharmaceutical preparation provided by the invention, the application in the medicine of especially hepatocarcinoma.
Pharmaceutical composition of the present invention is primarily of saikosaponin D and taurine composition.Pharmacological evaluation shows, by saikosaponin D and taurine conbined usage, can obviously strengthen its effect of anti hepatic fibrosis, improve the effect of the especially anti-hepatocarcinoma of its antitumor.
Experimentation shows, the Radix Bupleuri aglycon D generated after saikosaponin D hydrolysis has similar pharmacological action with taurine combination.Ester after chemical bond of saikosaponin D or its Radix Bupleuri aglycon D and taurine or salt also have similar pharmacological action.
Saikosaponin D Radix Bupleuri aglycon D taurine
The present invention require saikosaponin D to be hydrolyzed further to generate Radix Bupleuri aglycon D and the application of compositions in the medicine for the treatment of and prevention hepatic fibrosis, tumor especially hepatocarcinoma of taurine.The present invention also requires the application in the medicine for the treatment of and prevention hepatic fibrosis, tumor especially hepatocarcinoma of ester after chemical bond of saikosaponin D or its Radix Bupleuri aglycon D and taurine or salt further.
Pharmaceutical preparation of the present invention, its dosage form is oral agents or injection, preferred dosage form is tablet, capsule, granule, drop pill, dispersible tablet, liquid drugs injection or powder pin, more preferably injection, as liquid drugs injection, powder pin, the adjuvant that can add has filler, pH value regulator and appropriate solvent, most preferably solid orally ingestible, as tablet, capsule, granule etc., appropriate pharmaceutically useful adjuvant can be added for tablet, capsule, granule, drop pill, dispersible tablet.
Pharmaceutical preparation of the present invention, its preparation method is pharmaceutics conventional method, comprises saikosaponin D and taurine, and the step of the acceptable adjuvant mixing of medicine.
Pharmaceutical preparation of the present invention, its dosage form is oral agents or injection, preferred dosage form is tablet, capsule, granule, liquid drugs injection or powder pin, more preferably injection, as liquid drugs injection, powder pin, the adjuvant that can add has filler, pH value regulator and appropriate solvent, most preferably solid orally ingestible, as tablet, capsule, granule etc., appropriate pharmaceutically useful adjuvant can be added for tablet, capsule, granule.
Pharmaceutical preparation of the present invention, can oral administration use, and every day can take 1 ~ 4 time, each 1 ~ 3 dosage unit; Also can parenteral administration, use 1 every day, each 1 ~ 2 dosage unit.Described dosage unit refers to every agent, as every sheet of tablet, every of capsule etc.
In formula of the present invention composition, part of medicine is weight portion, and every portion can be 1 gram, also can be kilogram or ton, if with gram be unit, this formula forms and can be made into pharmaceutical preparation 1000 doses, is also above-mentioned 1000 dosage units.Described 1000 doses or 1000 dosage units refer to, the amount of the final drug dosage made, as made capsule preparations 1000,1000, tablet, injection 1000 bottles, granule 1000g etc., also large packaging can be made as granule, as 100-500 bag, can be specifically 100 bags, 125 bags, 200 bags, 250 bags, 500 bags etc., every bag can be used as 1 taking dose.
More than composition is by weight as proportioning, corresponding proportion can be installed when producing increase or reduce, as large-scale production can by kilogram in units of, or in units of ton, small-scale production also can in units of milligram, weight can increase or reduce, but the constant rate of medical material weight proportion between each composition.
Medicine of the present invention anti-hepatic fibrosis, antioxidation, suppression collage synthesis, improve hepatocyte injury, liver function protecting, antitumor, etc. in there is synergism.
Pharmaceutical composition of the present invention compared with prior art, has the following advantages:
(1) pharmacological evaluation shows, saikosaponin D and taurine combinationally use by pharmaceutical composition of the present invention, has anti-lipid peroxidation effect, and protection liver plasma membrane is stablized, and has certain inhibitory action to the synthesis of Liver Collagen during hepatic fibrosis.Wherein, taurine and saikosaponin D work in coordination with the effect of anti hepatic fibrosis using and can strengthen saikosaponin D.
(2) pharmaceutical composition of the present invention, by saikosaponin D and taurine use, to the growth inhibited of L-02 cell without positive effect, obvious to the growth inhibitory effect of HepG2 cell, illustrate, to tumor especially hepatocarcinoma, there is significant inhibitory action.
(3) pharmaceutical composition of the present invention, by saikosaponin D and taurine use, reduces saikosaponin D itself to hepatocellular toxic damages effect, reduces liver toxicity.
The beneficial effect of pharmaceutical composition of the present invention is set forth further below by way of experiment.Pharmaceutical composition of the present invention has following beneficial effect, but this should be interpreted as pharmaceutical composition of the present invention only has following beneficial effect.
Detailed description of the invention
The detailed description of the invention of form by the following examples, is described in further detail foregoing of the present invention.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following examples.All technology realized based on foregoing of the present invention all belong to scope of the present invention.In following examples, the adjuvant of each dosage form can be replaced with pharmaceutically acceptable adjuvant, or reduce, increase.Wherein, 10%PVPK30 ethanol, " in right amount " implication: for tablet, consumption is generally 2% ~ 5%, and concentration is generally 0.5% ~ 5%.
The preparation of embodiment 1 present composition tablet
1, prescription:
Prescription 1
| Saikosaponin D | 1g |
| Taurine | 100g |
| Microcrystalline Cellulose | 50g |
| Pregelatinized Starch | 100g |
| 10%PVPK30 ethanol | In right amount |
| Magnesium stearate | 3g |
| Preparation altogether | 1000 |
Prescription 2
| Saikosaponin D | 3g |
| Taurine | 200g |
| Microcrystalline Cellulose | 60g |
| Pregelatinized Starch | 100g |
| 10%PVPK30 ethanol | In right amount |
| Magnesium stearate | 3g |
| Preparation altogether | 1000 |
2, preparation technology:
It is for subsequent use that stock and adjunct pulverized 80 mesh sieves respectively; Prepared by granulation solution: getting PVP K30, to add concentration be the solution that 30 ~ 95% medicinal alcohols make 5 ~ 10%; Get stock and adjunct mixing, add granulation solution soft material processed in right amount, 20 orders are granulated, and after 50 ~ 70 DEG C of dryings, 18 order granulate, add magnesium stearate mixing; Measure granule content, capsule-filling, random detection loading amount; Finished product is examined entirely, packaging warehouse-in.
The preparation of the capsule of embodiment 2 pharmaceutical composition of the present invention
1, prescription:
Prescription 1
| Saikosaponin D | 0.5g |
| Taurine | 100g |
| Microcrystalline Cellulose | 50g |
| Pregelatinized Starch | 100g |
| 10%PVPK30 ethanol | In right amount |
| Magnesium stearate | 3g |
| Preparation altogether | 1000 |
Prescription 2
| Saikosaponin D | 2g |
| Taurine | 200g |
| Microcrystalline Cellulose | 60g |
| Pregelatinized Starch | 100g |
| 10%PVPK30 ethanol | In right amount |
| Magnesium stearate | 3g |
| Preparation altogether | 1000 |
2, preparation technology:
It is for subsequent use that stock and adjunct pulverized 80 mesh sieves respectively; Prepared by granulation solution: getting PVP K30, to add concentration be the solution that 30 ~ 95% medicinal alcohols make 5 ~ 10%; Get stock and adjunct mixing, add granulation solution soft material processed in right amount, 20 orders are granulated, and after 50 ~ 70 DEG C of dryings, 18 order granulate, add magnesium stearate mixing; Measure granule content, capsule-filling, random detection loading amount; Finished product is examined entirely, packaging warehouse-in.
The preparation of embodiment 3 medicament composition granule of the present invention
1, prescription:
Prescription 1:
| Saikosaponin D | 1g |
| Taurine | 200g |
| Icing Sugar | 1000g |
| 2%HPMC50% alcoholic solution | In right amount |
| Preparation altogether | 1000 bags |
Prescription 2:
| Saikosaponin D | 3g |
| Taurine | 300g |
| Icing Sugar | 1200g |
| 2%HPMC50% alcoholic solution | In right amount |
| Preparation altogether | 1000 bags |
2, concrete steps:
Stock and adjunct was pulverized 100 mesh sieves, for subsequent use; Take stock and adjunct according to recipe quantity, the method that raw material and Icing Sugar progressively increase with equivalent is mixed homogeneously, add 2%HPMC50% alcoholic solution in right amount, stir, make suitable soft material, cross 20 mesh sieves and granulate, 60 DEG C of oven dry, cross 18 mesh sieve granulate; Sampling, in semi-finished product chemical examination granule, the content of principal agent, determines loading amount, subpackage; Finished product is examined entirely, packaging warehouse-in.
The preparation of embodiment 4 present composition liquid drugs injection
1, prescription:
Prescription 1:
| Saikosaponin D | 2g |
| Taurine | 100g |
| Polyoxyethylene sorbitan monoleate | 20g |
| Water for injection | 5000ml |
| Preparation altogether | 1000 |
Prescription 2:
| Saikosaponin D | 5g |
| Taurine | 150g |
| Polyoxyethylene sorbitan monoleate | 50g |
| Water for injection | 10000ml |
| Preparation altogether | 1000 |
2, preparation technology:
Production ampoule dosing container tool, instrument and equipment etc. are carried out clear up, degerming, depyrogenation; Take stock and adjunct by prescription, get the water for injection that polyoxyethylene sorbitan monoleate adds dosing amount 80%, stirring and dissolving; Add the needle-use activated carbon of dosing amount 0.05%, stir 15min, filter, de-charcoal, adds raw material, stirring and dissolving in solution, and measure and regulate the pH value of solution, benefit adds to the full amount of water for injection, standardize solution; Medicinal liquid, through the microporous filter membrane fine straining of 0.22 μm, checks clarity, the inspection of semifinished product; Medicinal liquid is loaded in ampoule, 100 DEG C of flowing steam sterilization 30min, leak detection, lamp inspection; Finished product is examined entirely, packaging warehouse-in.
The preparation of embodiment 6 pharmaceutical composition powder of the present invention pin
1, prescription:
Prescription 1:
| Saikosaponin D | 2g |
| Taurine | 100g |
| Dextran | 100g |
| Water for injection | 5000ml |
| Preparation altogether | 1000 |
Prescription 2:
| Saikosaponin D | 5g |
| Taurine | 200g |
| Dextran | 200g |
| Water for injection | 10000ml |
| Preparation altogether | 1000 |
2, preparation technology:
Cillin bottle used for production, plug and dosing container tool, instrument and equipment etc. are carried out clear up, degerming, depyrogenation; Take stock and adjunct by prescription, dextran is added dosing amount 80% water for injection, stirring and dissolving; Then add the needle-use activated carbon of dosing amount 0.05%, stir 15min, filter, de-charcoal, adds raw material, stirring and dissolving in solution, and measure and regulate the pH value of solution, benefit adds to the full amount of water for injection, standardize solution; Medicinal liquid, through the microporous filter membrane fine straining of 0.22 μm, checks clarity, the inspection of semifinished product; Medicinal liquid subpackage 2ml in cillin bottle, half tamponade, lyophilizing, tamponade, Zha Gai; Finished product is examined entirely, packaging warehouse-in.
Embodiment 7 biological test
Experiment one, taurine are to the potentiation of SSd anti-hepatic fibrosis.
Laboratory animal: healthy wistar rat, male and female half and half, body weight 20 ~ 25 g, is provided by Shandong University's Experimental Animal Center.
Experiment reagent and medicine
:saikoside d sterling (>=98%), taurine, all purchased from Zhong Shankangzhi source bio tech ltd, faces the used time becomes desired concn solution with normal saline dilution.Colchicines tablets, purchased from Yunnan Plant Pharmaceutical Industry Co., Ltd., sodium chloride injection is purchased from Shangdong Changfu Jiejing Pharmaceutical Industry Co., Ltd..
Pharmaceutical composition MC1:SSd(0.50 mg/kg)
MC2:SSd(0.25 mg/kg)+taurine (0.75 g/kg)
MC3:SSd(0.50 mg/kg)+taurine (0.75 g/kg)
Experimental technique: all rats stablized raising after 3 days, is divided into Normal group (A), model group (B), medicine 1 ~ 3 group (C1, C2, C3) and colchicines tablets positive controls (D) at random by body weight.Each group according to 10ml/kg rat body weight gastric infusion.B, C1, C2, C3, D group the 1st week gavage 10% ethanol, 2nd ~ 3 weeks gavage 5% ethanol, lumbar injection porcine blood serum 0.5mL, 2 times weekly; And raise with the high fat Low protein diet of correspondence (add 10% Adeps Sus domestica by 89.5% simple Semen Maydis powder, 0.5% cholesterol is made).C1 group gavage gives MC1, and C2 group gavage gives MC2, and C3 group gavage gives MC3, and D group gavage gives colchicines tablets 0.18mg/kg.Every day 1 time, continuous 7 days.After last administration 2 h, positive drug group gavage colchicines tablets 0.18mg/kg, medicine 1 ~ 3 group (C1, C2, C3), normal group gavage distilled water is also raised with chow diet.Successive administration 3 weeks, whole experimental period is 3 weeks.After last administration 2 h, pluck eyeball and get blood, centrifugalize serum, measure serum superoxide dismutases (SOD), malonaldehyde (MDA), hyaluronic acid (HA) level.
Experimental result: compared with Normal group, model control group rat blood serum SOD vigor significantly reduces (P<0.01), and MDA, HA content obviously raises (P<0.01), histopathologic examination finds that hepatic tissue is obviously impaired, and occur downright bad, modeling success is described.Compared with model control group, positive controls and each administration group C1, C2, C3 all significantly can raise rat blood serum SOD vigor (P<0.05 or P<0.01), MDA, HA content obviously reduces, and liver tissue injury significantly alleviates.SSd obviously can suppress the change of These parameters, the SSd after dosage reduces by half and taurine use, and inhibition is obviously better than alone SSd group, and the liver protection effect of C3 group medicine is best.
Table 1 pharmaceutical composition of the present invention is to the effect of hepatic fibrosis rats
| Group | Dosage | MDA(nmol/ml) | SOD(U/ml) | HA(ng/ml) |
| A | — | 6.18±0.47 | 183.11±29.57 | 126.46±26.07 |
| B | — | 8.42±0.67** | 140.69±13.38** | 188.12±19.34** |
| C1 | 0.50mg/kg | 7.82±1.37 | 151.41±25.59 | 167.71±25.52 |
| C2 | 0.25mg/kg+0.75g/kg | 7.43±1.46* | 163.82±25.64* | 149.36±37.84* |
| C3 | 0.50mg/kg+0.75g/kg | 7.19±1.58** | 170.96±17.41** | 137.62±28.47** |
| D | 0.18mg/kg | 7.42±1.19* | 175.56±14.68* | 143.46±18.22* |
Note: compare with Normal group, * P<0.05, * * P<0.01, * * * P<0.001
Conclusion: this result of study shows, SSd can make fibrosis rat blood serum SOD vigor have enhancing, and reduces the content of MDA.The HA content of rising can be made significantly to reduce simultaneously.Prompting SSd has anti-lipid peroxidation effect, has certain inhibitory action to the synthesis of Liver Collagen during hepatic fibrosis.Wherein, taurine and SSd work in coordination with the effect of anti hepatic fibrosis using and can strengthen SSd.
Experiment two, inhibitory action to L-02 cell and HepG2 Growth of Cells
Experiment reagent and medicine
:l-02 cell strain, HepG2 cell strain (Shanghai Inst. of Cytobiology, Chinese Academy of Sciences provides).Four tetrazolium bromides (MTT) (Sigma company); Propidium iodide (PI) (Sigma company); Dimethyl sulfoxide (DMSO) (Sigma company); New-born calf serum (Hangzhou Ilex purpurea Hassk.[I.chinensis Sims biological engineering company limited); DMEM (Gibco BRL company); Amresco company of the trypsin U.S.); Pen .-Strep solution (the green skies, Hangzhou biotechnology research institute); PBS (Amresco company of the U.S.).
Pharmaceutical composition NB1:SSd(2.50 μm ol/L)
NB2:SSd(1.25 μm of ol/L)+taurine (0.50 μm of ol/L)
NB3:SSd(2.50 μm of ol/L)+taurine (0.50 μm of ol/L)
Experimental technique: L-02 cell, HepG2 cell all with containing 10% deactivation new-born calf serum DMEM culture medium and be 7.2 ~ 7.4 by sodium hydroxide adjust ph, be placed in 37 DEG C, 5% CO
2cultivate in incubator, tumor cell culture liquid is changed every day, and L-02 cell changes liquid 1 time in every 2 days.In experiment, cell used is all in exponential phase viable count and is greater than 95%.Take the logarithm trophophase L-02 cell, HepG2 cell Digestive system digestion after, with add 10% serum DMEM culture fluid piping and druming make 4 × 10
3/ mL cell suspension, adds 96 well culture plates, and every hole 200 μ L, at 5% CO
2, 37 DEG C of incubators cultivate 24 h.After cell is completely adherent, be divided into blank group (A), medicine 1 ~ 3 group (B1, B2, B3).A group gives 200 μ L culture medium, and B1 group gives the culture medium containing NB1, and B2 group gives the culture medium containing NB2, and B3 group gives the culture medium containing NB3, carries out MTT staining analysis after continuing cultivation 24 h.Blank control wells adds the pastille serum-free medium of equivalent and acellular, and each hole adds culture medium to 200 μ L, and incubator hatches 24h, carries out MTT staining analysis after continuing to hatch 24 h after changing fresh culture.Under the wavelength of microplate reader 570nm, record each hole OD value, and carry out date processing to specifications.
Experimental result: compared with Normal group, B1, B2, B3 group all can suppress the growth (P<0.05 or P<0.01) of L-02 cell, SSd and taurine use, and inhibition is without obvious change; Compared with Normal group; B1, B2, B3 group all can suppress the growth (P<0.05 or P<0.01) of HepG2 cell; SSd and taurine are used; inhibition is better, and action effect is still better than alone normal dose SSd when reducing SSd consumption.
Table 2 pharmaceutical composition of the present invention is to the inhibitory action of human liver cells L-02
| Group | Dosage | Suppression ratio (%) |
| A | — | 0.26±0.03 |
| B1 | 2.50μmol/L | 38.82±1.37* |
| B2 | 2.50μmol/L +0.50μmol/L | 36.43±1.46* |
| B3 | 5.00μmol/L +0.50μmol/L | 93.42±1.19** |
Note: compare with Normal group, * P<0.05, * * P<0.01
Table 3 pharmaceutical composition of the present invention is to the inhibitory action of human liver cancer cell HepG2
| Group | Dosage | Suppression ratio (%) |
| A | — | 0.12±0.13 |
| B1 | 2.50μmol/L | 14.89±0.17 |
| B2 | 2.50μmol/L +0.50μmol/L | 35.27±1.38* |
| B3 | 5.00μmol/L +0.50μmol/L | 85.35±1.19** |
Note: compare with Normal group, * P<0.05, * * P<0.01
Experimental result: compared with Normal group, SSd can suppress the growth (P<0.05 or P<0.01) of L-02 cell, SSd and taurine use, and inhibition is without obvious change; Compared with Normal group, SSd can suppress the growth (P<0.05 or P<0.01) of HepG2 cell, SSd and taurine use, and inhibition is better, illustrates there is significant inhibitory action to tumor.
Claims (10)
1. a pharmaceutical composition, is characterized in that being made up of saikosaponin D and taurine, optionally also containing the acceptable adjuvant of medicine.
2. pharmaceutical composition as claimed in claim 1, wherein the mass ratio of saikosaponin D and taurine is 0.1-100:0.1-800, preferred 0.1-20:0.5-50.
3. pharmaceutical composition as claimed in claim 1 or 2, it is also containing the receivable adjuvant of medicine.
4. the pharmaceutical composition according to any one of claim 1-3, wherein every 1000 dosage units contain saikosaponin D 0.1 ~ 100 part, taurine 0.1 ~ 800 part, preferably containing saikosaponin D 0.1 ~ 20 part, containing taurine 0.5 ~ 50 part.
5. the pharmaceutical composition according to any one of claim 1-4, wherein also containing the acceptable adjuvant of medicine, its dosage form is oral agents or injection, and preferred dosage form is tablet, drop pill, dispersible tablet, capsule, granule, liquid drugs injection or powder pin.
6. the pharmaceutical composition according to any one of claim 1-5, described pharmaceutical composition is used for prevention and therapy hepatic fibrosis, the preferred hepatocarcinoma of tumor.
7. the pharmaceutical composition according to any one of claim 1-5, described pharmaceutical composition be used for the treatment of and/or prevent the hepatitis caused by virus, antibacterial, invasive organism, drug induced injury, immune mediating damage and specificity and nonspecific lipid liver the hepatic fibrosis disease that is in progress.
8. the pharmaceutical composition according to any one of claim 1-5 is for the preparation of the application treated and/or prevented in the medicine of hepatocarcinoma.
9. the pharmaceutical composition according to any one of claim 1-5 for the preparation of the hepatitis treated and/or prevented caused by virus, antibacterial, invasive organism, drug induced injury, immune mediating damage and specificity and nonspecific lipid liver the application in the medicine of hepatic fibrosis disease that is in progress.
10. apply as described in claim 8-9, wherein said pharmaceutical composition is oral agents or injection, and preferred dosage form is tablet, drop pill, dispersible tablet, capsule, granule, liquid drugs injection or powder pin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510052476.4A CN104688758A (en) | 2015-02-02 | 2015-02-02 | Medicine composition of compound saikosaponin D and application of medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510052476.4A CN104688758A (en) | 2015-02-02 | 2015-02-02 | Medicine composition of compound saikosaponin D and application of medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104688758A true CN104688758A (en) | 2015-06-10 |
Family
ID=53336584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510052476.4A Pending CN104688758A (en) | 2015-02-02 | 2015-02-02 | Medicine composition of compound saikosaponin D and application of medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104688758A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634587A (en) * | 2004-12-06 | 2005-07-06 | 北京阜康仁生物制药科技有限公司 | Compound preparation for treating urgent and chronic liver diseases and its preparation method |
| CN103479656A (en) * | 2012-06-12 | 2014-01-01 | 上海市中医医院 | Application of saikoside d in preparation of anti-hepatic fibrosis disease drugs |
-
2015
- 2015-02-02 CN CN201510052476.4A patent/CN104688758A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634587A (en) * | 2004-12-06 | 2005-07-06 | 北京阜康仁生物制药科技有限公司 | Compound preparation for treating urgent and chronic liver diseases and its preparation method |
| CN103479656A (en) * | 2012-06-12 | 2014-01-01 | 上海市中医医院 | Application of saikoside d in preparation of anti-hepatic fibrosis disease drugs |
Non-Patent Citations (1)
| Title |
|---|
| 李晓杰等: "中药抗肝纤维化研究进展", 《中国中医药信息杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geng et al. | Preventive and therapeutic effect of Ganoderma lucidum on kidney injuries and diseases | |
| CN103880910B (en) | A kind of preparation method and its usage of Cyclosiversigenin | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN111166734A (en) | Use of naphthoquinones to treat pneumonia caused by pathogenic organisms | |
| KR20080074872A (en) | Herbal powder extracts and methods of preparing and using the same | |
| CN111035649A (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| AU2005204044B2 (en) | Antiaging composition | |
| CN104688760A (en) | Pharmaceutical composition composed of saikoside A and taurine and use thereof | |
| WO2015192758A1 (en) | Anti-tumor pharmaceutical application of pentacyclic triterpene saponin compounds of szechuan melandium root | |
| CN101108872B (en) | Plants natural base extract and formulated product and use thereof | |
| CN102475698B (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN112370496A (en) | Application of effective components of Lycii folium in preparing medicine for preventing or treating hepatic fibrosis | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN101474173B (en) | Application of cumarin coumpound Murraya jasminorage ketone in preparing anti-tumor medicament | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN104688758A (en) | Medicine composition of compound saikosaponin D and application of medicine composition | |
| CN102716230A (en) | Novel applications of cape jasmine extract product in preparation of drugs | |
| CN108785383B (en) | Antibacterial gynecological external medicine composition and preparation method and application thereof | |
| CN106890268B (en) | A kind of composition for treating leukaemia and preparation method thereof | |
| CN104997818A (en) | Application of total saponins of helleborus thibetanus franch in preparing drugs for preventing and treating liver injuries | |
| CN101721405B (en) | Application of diacetylbaicalein in preparation of drugs used for curing or preventing liver diseases | |
| KR20190003190A (en) | A Composition for Preventing or Treating Postmenopausal Syndrome Comprising Oriental Herbal Extract | |
| CN105816487A (en) | Novel application of salacia prinoides | |
| CN104688759A (en) | Compound preparation for preventing and treating immune hepatic fibrosis and hepatic cirrhosis | |
| CN104173387B (en) | The pharmaceutical usage of clarinet pore fungi and the pharmaceutical composition for treating tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150610 |
|
| RJ01 | Rejection of invention patent application after publication |